JPMorgan Chase & Co. lifted its position in shares of Waters Corporation (NYSE:WAT – Free Report) by 54.4% during the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 332,447 shares of the medical instruments supplier’s stock after buying an additional 117,098 shares during the quarter. JPMorgan Chase & Co. owned approximately 0.56% of Waters worth $99,675,000 at the end of the most recent quarter.
A number of other institutional investors have also bought and sold shares of the business. Integrated Wealth Concepts LLC lifted its position in shares of Waters by 2.9% in the first quarter. Integrated Wealth Concepts LLC now owns 1,048 shares of the medical instruments supplier’s stock valued at $386,000 after acquiring an additional 30 shares in the last quarter. Exchange Traded Concepts LLC raised its stake in Waters by 5.9% during the 3rd quarter. Exchange Traded Concepts LLC now owns 630 shares of the medical instruments supplier’s stock valued at $189,000 after purchasing an additional 35 shares during the period. Penserra Capital Management LLC lifted its holdings in Waters by 13.1% in the 2nd quarter. Penserra Capital Management LLC now owns 327 shares of the medical instruments supplier’s stock worth $114,000 after purchasing an additional 38 shares in the last quarter. Tokio Marine Asset Management Co. Ltd. boosted its stake in Waters by 1.8% in the 3rd quarter. Tokio Marine Asset Management Co. Ltd. now owns 2,264 shares of the medical instruments supplier’s stock worth $679,000 after purchasing an additional 41 shares during the period. Finally, CW Advisors LLC grew its holdings in Waters by 2.0% during the 2nd quarter. CW Advisors LLC now owns 2,112 shares of the medical instruments supplier’s stock valued at $737,000 after buying an additional 42 shares in the last quarter. Hedge funds and other institutional investors own 94.01% of the company’s stock.
Analyst Upgrades and Downgrades
WAT has been the topic of several research analyst reports. Weiss Ratings reissued a “hold (c)” rating on shares of Waters in a report on Wednesday, January 21st. Guggenheim reiterated a “buy” rating and issued a $440.00 price target on shares of Waters in a report on Tuesday, February 10th. HSBC started coverage on shares of Waters in a report on Tuesday, January 27th. They set a “buy” rating and a $460.00 price objective for the company. Wells Fargo & Company reduced their target price on Waters from $415.00 to $355.00 and set an “equal weight” rating on the stock in a report on Wednesday, February 11th. Finally, Citigroup began coverage on Waters in a research report on Tuesday, February 10th. They issued a “buy” rating and a $425.00 target price on the stock. Two investment analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Waters currently has a consensus rating of “Moderate Buy” and an average price target of $393.84.
Waters Stock Performance
Waters stock opened at $333.41 on Monday. The company’s 50-day moving average price is $374.36 and its 200-day moving average price is $349.65. The company has a quick ratio of 1.01, a current ratio of 1.41 and a debt-to-equity ratio of 0.41. The company has a market cap of $19.85 billion, a PE ratio of 30.96, a price-to-earnings-growth ratio of 2.30 and a beta of 1.18. Waters Corporation has a twelve month low of $275.05 and a twelve month high of $414.15.
Waters (NYSE:WAT – Get Free Report) last released its quarterly earnings results on Monday, February 9th. The medical instruments supplier reported $4.53 EPS for the quarter, topping the consensus estimate of $4.50 by $0.03. Waters had a return on equity of 34.79% and a net margin of 20.30%.The company had revenue of $932.36 million during the quarter, compared to analyst estimates of $928.17 million. During the same quarter last year, the business posted $4.10 earnings per share. The firm’s revenue was up 6.9% on a year-over-year basis. Waters has set its FY 2026 guidance at 14.300-14.500 EPS and its Q1 2026 guidance at 2.250-2.350 EPS. On average, equities research analysts forecast that Waters Corporation will post 12.86 EPS for the current fiscal year.
Waters Company Profile
Waters Corporation is a global provider of analytical instruments, software and services for laboratory and research applications. The company designs, manufactures and sells technologies centered on liquid chromatography, mass spectrometry, separation science, and related sample preparation and detection systems. Its product portfolio includes chromatographs, mass spectrometers, columns and consumables, laboratory informatics and workflow software, as well as technical support and training services that help customers run and interpret complex analyses.
Waters serves a wide range of end markets that include pharmaceutical and biotechnology companies, contract research and testing laboratories, academic and government research institutions, clinical diagnostics, food and environmental testing, and industrial and chemical manufacturers.
See Also
- Five stocks we like better than Waters
- The gold chart Wall Street is terrified of…
- Buy this Gold Stock Before May 2026
- What a Former CIA Agent Knows About the Coming Collapse
- This $15 Stock Could Go Down as the #1 Stock of 2026
- “Fed Proof” Your Bank Account with THESE 4 Simple Steps
Receive News & Ratings for Waters Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Waters and related companies with MarketBeat.com's FREE daily email newsletter.
